The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US, answers the question: Is CC-93269, a novel BCMA T-cell engager, safe and efficacious for patients with relapsed/refractory multiple myeloma (RRMM)?
Luciano J Costa presents the first-in-human phase I results of CC-93269 for patients with RRMM. Safety analysis showed cytokine release syndrome (CRS) occurred in 75% of patients with most cases being grade 1-2. However, one death due to CRS occurred. In relation to efficacy, as the dose increased, the responses were faster and more profound. At a dose of 10mg, 89% of patients responded, with 44% in complete response which were all minimal residual disease (MRD)-negative. Patient accrual is ongoing.